

**WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE
CURRICULUM VITAE**


NAME:

Curt Daniel Furberg, M.D., Ph.D.

SOCIAL SECURITY NUMBER:

ADDRESS:

Residence:



Business:

Department of Public Health Sciences
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1063

PERSONAL INFORMATION:

EDUCATION:

1956-1958

University of Uppsala
Uppsala, Sweden
MK (Medicine Kandidat)
(undergraduate)

1959-1963

University of Umea
Umea, Sweden
M.L. (M.D. equivalent)

EDUCATION (Continued):

1968 University of Umeå
Umeå, Sweden
Thesis: "Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance"
(Advisor: Professor H. Linderholm)
(Ph.D. - equivalent)

POSTDOCTORAL TRAINING:

1973	ECFMG
1974 - 1976	Biostatistics: Five courses in the Graduate Program (15 credits) National Institutes of Health Bethesda, Maryland
1977	Epidemiology: Two courses in the Graduate Program (5 credits) National Institutes of Health Bethesda, Maryland
1977	Three courses at the 12th Graduate Summer Session in Epidemiology (8 credits) School of Public Health University of Minnesota



PROFESSIONAL LICENSURE:

1963 Sweden. —

EMPLOYMENT:

1999-Present	Director Office of Academic Program Development Wake Forest University Baptist Medical Center Winston-Salem, North Carolina
1989 - 1999	Chairman Department of Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina

EMPLOYMENT (Continued):

1986 - 1989	Director Center for Prevention Research and Biometry Bowman Gray School of Medicine Winston-Salem, North Carolina
1985 - 1986	Associate Director Clinical Applications and Prevention Program Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1984 - 1985	Acting Associate Director Clinical Applications and Prevention Program Division of Epidemiology and Clinical Applications National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1982 - 1984	Deputy Associate Director Clinical Applications and Prevention Program Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1979 - 1985	Chief, Clinical Trials Branch Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1974 - 1979	Visiting Scientist Clinical Trials Branch National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland
1973 - 1974	Research Fellow Department of Internal Medicine Minneapolis Lipid Research Center - University of Minnesota Minneapolis, Minnesota
1968 - 1974	Chairman Department of Clinical Physiology Central Hospital Boden, Sweden

EMPLOYMENT (Continued):

1967 - 1968	Acting Deputy Chairman Department of Clinical Physiology University Hospital Umea, Sweden
1963 - 1966	Physician Department of Clinical Physiology University Hospital Umea, Sweden

Academic Experience:

1989 - Present	Professor of Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina
1987 - Present	Adjunct Associate Professor Department of Family Medicine Uppsala University Uppsala, Sweden
1986 - 1989	Professor of Medicine Wake Forest University School of Medicine Winston-Salem, North Carolina
1984 - 1987	Clinical Professor Department of Community and Family Medicine Georgetown University School of Medicine Washington, D.C.
1968 - 1986	Associate Professor of Clinical Physiology University of Umea Umea, Sweden

Teaching Experience:

1986 - Present	Wake Forest University School of Medicine Winston-Salem, North Carolina
1984 - 1986	Georgetown University School of Medicine Washington, D.C.
1981 - 1985	Faculty Appointment Graduate School of National Institutes of Health Bethesda, Maryland
1967 - 1968	Acting Professor Department of Clinical Physiology University of Umea (3 months) Umea, Sweden

OTHER PROFESSIONAL ACTIVITIES:**A. RESEARCH ACTIVITIES****1. Principal Investigator**

1970 - 1974	Boden Multifactor Primary Prevention Trial
1970 - 1975	World Health Organization European Ischemic Heart Disease Register Study (Center 17 Boden)
1987 - 1993	Pravastatin, Lipids and Atherosclerosis in the Carotids (PLAC-2) Study
1988 - 1995	Cardiovascular Health Study (NHLBI) Bowman Gray School of Medicine Field Center
1988 - 1994	Asymptomatic Carotid Artery Progression Study (NHLBI)
1989 - 1992	Prevention of Functional Deterioration in Hospitalized Elderly - PREHAB (John A. Hartford Foundation)
1990 - 1992	Urinary Incontinence in Community-Dwelling Women (WFUSM Subcontract)
1992 - 1999	Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial - PREVENT (Pfizer)
1992 - 1999	Women's Health Initiative - Clinical Facilities Center (WFUSM Subcontract)
1999 - Present	Ginkgo Evaluation Memory Study (GEMS) Clinical Coordinating Center

2. Scientific Project Officer, NHLBI

1974 - 1980	Aspirin Myocardial Infarction Study
1976 - 1985	Multiple Risk Factor Intervention Trial
1977 - 1985	Beta-blocker Heart Attack Trial
1980 - 1985	Systolic Hypertension in the Elderly Program
1982 - 1984	Hypertension Prevention Trial
1982 - 1984	Cardiac Arrhythmia Pilot Study
1983 - 1985	Program on Surgical Control of the Hyperlipidemias
1984	Studies of Left Ventricular Dysfunction
1984 - 1985	Preventive Cardiology Academic Awardees Program

3. Data & Safety Monitoring Committees

1975 - 1979	Aspirin Myocardial Infarction Study
1978 - 1982	Beta-blocker Heart Attack Trial
1980 - 1985	Systolic Hypertension in the Elderly Program
1981 - 1982	Multiple Risk Factor Intervention Trial
1982 - 1985	Hypertension Prevention Trial

1983 - 1993	Diabetes Control and Complications Trial
RESEARCH ACTIVITIES (continued):	
1983 - 1985	Program on Surgical Control of the Hyperlipidemias
1985 - 1987	Prevention of Atherosclerotic Complications with Ketanserin
1986 - 1989	Digibind Post-Marketing Surveillance Study
1986 - 1994	Fluorouracil Filtering Surgery Study (Chairman)
1987 - 1988	Tolrestat Retinopathy Studies (Chairman)
1987 - 1988	Ultradol Rheumatoid Arthritis Trial (Chairman)
1987 - 1989	Shock Resuscitation Clinical Trials (Chairman)
1987 - 1988	Cilazapril/Nitrendipine Hypertension Trials
1987 - Present	Advanced Glaucoma Intervention Study (Chairman)
1988 - 1996	Post Coronary Artery Bypass Graft Studies
1988 - 1990	Glaxo Restenosis and System Project (Chairman)
1988 - 1994	Scandinavian Simvastatin Survival Study
1988 - 1990	Quality of Life in Hypertension Study
1989 - 1996	Cholesterol and Recurrent Events Study
1989 - 1991	CONSENSUS II Study (Chairman)
1989 - 1991	Ethmozine/Encainide PES Study
1989 - 1992	Canadian Coronary Atherosclerosis Intervention Trial (Chairman)
1990 - 1992	Post-Angioplasty Restenosis Ketanserin Trial
1990 - 1997	CABG Patch Trial (Chairman)
1991 - 1996	Quinapril Ischemic Event Trial (Chairman)
1991 - Present	Age-related Eye Diseases Study
1992 - 1993	FLOLAN International Randomized Survival Study
1992 - 1997	Assessment of Treatment with Lisinopril and Survival
1992 - 1998	Randomized Aldactone Efficacy Study
1993 - 1996	Coumadin Aspirin Reinfarction Study
1993 - 1996	WHO Programme for the Prevention of Blindness (Chairman)
1993 - Present	Early Manifest Glaucoma Trial (Chairman)
1994 - 1996	Evaluation of Losartan in the Elderly (Chairman)
1994 - 1999	Heart Outcomes Prevention Evaluation (HOPE)
1994 - 1997	Accupril Congestive Heart Failure Investigation and Economic Variable Evaluation (ACHIEVE)
1995 - 1997	Myloral in Multiple Sclerosis Trial (Chairman)
1995 - 1998	Trials of Amylin in Diabetes (Amylin)
1997 - 1998	CV-2619/PNRP 001 in Alzheimer's Disease (Takeda America)
1997 - 1999	Effects of Losartan on Mortality in CHF (ELITE II) (Chairman)
1998 - 1999	Melaccine plus Interferon versus Interferon in Malignant Melanoma (CATO Research)
1998 - 2001	Adenosine in Acute MI (MEDR640), Chairman (ClinTrials Research)
1998 - Present	Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL)
1999 - Present	Eplerenone in Heart Failure Post Acute Myocardial Infarction (EPHESUS)
1999 - Present	Lung Health Study
2000 - Present	Selenium and Vitamin E Chemoprevention Trial (SELECT) (Southwest Oncology Group)

2000 - Present

Heart Outcomes Prevention Evaluation II

B. LEADERSHIP

1. Steering/Investigators Committee

1988 - 1994	Chair, Steering Committee of the Multicenter Isradipine Diuretic Atherosclerosis Study Sandoz Research Institute
1989 - Present	Chair, Steering Committee of the Cardiovascular Health Study National Heart, Lung, and Blood Institute
1992 - Present	Chair, Investigators Committee of the Heart, Estrogen-Progestin Replacement Study Wyeth-Ayerst
1992 - 1999	Co-Chair, Steering Committee of Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial Pfizer Laboratories
1993 - 1995	Chair, Executive Committee
1993 - 1996	Chair, Publications & Presentations Subcommittee
1993 - 1995	Member, Management Committee
1995 - 1998	Performance Monitoring Committee Women's Health Initiative National Institutes of Health
1993 - Present	Chair, Steering Committee of the Antihypertensive Lipid-Lowering to prevent Heart Attack Trial National Heart, Lung, and Blood Institute
1992 - Present	Chair, Prospective Pravastatin Pooling Project Bristol-Myers Squibb
1999 - Present	Chair, Steering Committee of Ginkgo Evaluation Memory Study National Heart, Lung, and Blood Institute

2. Professional Organizations

1982 - 1984	Member and Chairman, Program Committee
1990 - 1991	Society for Clinical Trials
1984 - 1988	Secretary, Society for Clinical Trials
1992 - 1993	President
1993 - 1994	Past President Society for Clinical Trials
1992 - 1994	Member, Public Affairs Policy Committee American Heart Association Dallas, Texas
1992 - 1995	Member, Long Range Planning Committee

Council for Epidemiology and Prevention
American Heart Association

LEADERSHIP (continued)

1994 - 1998	Member, Advisory Board of Controlled Clinical Trials
1999 - Present	Member, Executive Council American Society of Hypertension

3. Intramural Committees

1989 - 1996	Acting Director, Nutrition Center Bowman Gray School of Medicine Winston-Salem, North Carolina
-------------	--

C. EXTRAMURAL ACTIVITIES

1. Government

1983 - 1985	Bilateral Exchange Program West Germany (NHLBI)
1984 - 1985	Equal Employment Opportunity Committee National Heart, Lung, and Blood Institute
1984 - 1985	Training Committee National Heart, Lung, and Blood Institute
1984 - 1985	Working Group to Revise Statement on Hypertension in the Elderly National Heart, Lung, and Blood Institute
1989 - 1991	Member
1991 - 1993	Chairman Clinical Applications and Prevention Advisory Committee National Heart, Lung, and Blood Institute
1992 - 1993	Member, NIDDK Planning Committee
1992 - 1993	Chair, NHLBI Planning Committee NIDDM Clinical Trial
1992 - 1993	Member, Task Force on Research in Epidemiology and Prevention of CVD National Heart, Lung, and Blood Institute
1996 - Present	Member, Board of Directors North Carolina Institute of Medicine

2. Editorial Boards

1983 - 1986	Circulation
1983 - 1987	Controlled Clinical Trials
1987 - 1990	Cardiovascular Drugs and Therapy
1988 - 1995	Journal of Drug Development

EXTRAMURAL ACTIVITIES (continued):

1989 - 1998	Journal of Internal Medicine
1990 - 1997	Annals of Epidemiology
1991 - 1997	Cardiology in the Elderly
1992 - 1997	American Journal of Geriatric Cardiology
1996 - Present	Evidence-Based Cardiovascular Medicine
1996 - Present	American Heart Journal
1999 - Present	Current Controlled Trials in Cardiovascular Medicine (Editor)
2001 - Present	Fundamental and Clinical Pharmacology (Field Editor)
2001 - Present	Cardiovascular Diabetology

3. Consultations

**1971 - 1972 Temporary Advisor
WHO's Working Group on IHD Registers
Copenhagen, Denmark**

1973 Temporary Advisor
 WHO's Working Group of Methodology
 Multicenter Preventive Trials in IHD
 Innsbruck, Austria

1982 - 1985	Food and Drug Administration
1983 - 1987	Temporary Advisor, WHO
1988 - 1990	International Cardiovascular Advisory Committee, Glaxo
1991 - 1993	University of Wisconsin Clinical Cancer Center Advisory Committee

4. Professional Memberships

American Heart Association
American Heart Association Council of Epidemiology
International Society and Federation of Cardiology
Society for Clinical Trials
American Society of Hypertension

D. ADMINISTRATIVE ACTIVITIES

1. Intramural

1986 - 1992

Acting Associate Director of Cancer Control
WFU Cancer Center
Bowman Gray School of Medicine

ADMINISTRATIVE ACTIVITIES (continued):

1988 - 1989

Chair

1989 - 1993

Chair

Member

General Clinical Research Center Committee

**General Clinical Research Center
Bowman Gray School of Medicine**

1990 - 1994

Co-chair, Executive Committee Target Health
Bowman Gray School of Medicine

1992 - 1994

Co-chair, Medical Center Health Services

Steering Committee

Steering Committee

2. Search Committees

1981

**Chair, Search Committee for Chief, Preventive Cardiology
Branch**
National Heart, Lung, and Blood Institute

1982

Chair, Search Committee for Chief, Mathematical and
Applied Statistics Branch
National Heart, Lung, and Blood Institute

1987 - 1998

Member, Chair Internal Medicine
Chair, Head Section of General Internal Medicine
Member, Head Section of Cardiology
Member, Director of WFU Comprehensive Cancer C
Chair, Associate Dean for Research
Director, Nutrition Center

E. HONORS AND AWARDS

1983

National Institutes of Health Director's Award

BIBLIOGRAPHY:

Monographs and Textbooks:

Furberg C. Effects of beta-adrenergic blockade on ECG, physical working capacity and central circulation with special reference to autonomic imbalance. *Acta Med Scand* 1968; (suppl 488).

Braunwald E, Friedewald WT, Furberg CD, eds. Proceedings of the workshop on platelet-active drugs in the secondary prevention of cardiovascular events. *Circulation* 1980;62(suppl V).

Furberg CD, Friedewald WT, Eberlein KA, eds. Proceedings of the workshop on implications of recent beta-blocker trials for post-myocardial infarction patients. *Circulation* 1983;67(suppl I).

Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: LeJacq, 1984.

Wenger NK, Furberg CD, Pitt E, eds. Coronary heart disease in the elderly. New York: Elsevier, 1986.

Furberg B, Furberg C. All that glitters is not gold. What clinicians need to know about clinical trials. North Carolina: Jostens, 1994.

Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 3rd ed. St. Louis: Mosby, 1996; New York: Springer-Verlag, 1998.

Chapters in Books:

Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Lipoprotein pattern in IHD. In: Tibblin G, Keys A, Werko L, eds. Preventive cardiology. Stockholm: Almqvist & Wiksell, 1972:166-170.

Lundkvist L, Furberg C, Svardsudd K. Special problems concerning myocardial infarction in Northern Sweden (Norrbotten). In: Bylund E, Linderholm H, Rune O, eds. Ecological problems of the Circumpolar Area. Lulea: Norrbottens Museum, 1974:202-207.

Svardsudd K, Furberg C, Lundkvist L. Latent need of medical service in Northern Sweden (Norrbotten) with special reference to cardiovascular diseases. In: Bylund E, Linderholm H, Rune O, eds. Ecological problems of the Circumpolar Area. Lulea: Norrbottens Museum, 1974:209-211.

Berg K, Dahlen G, Erikson C, Frick H, Furberg CD, Wiljasalo M. Pre-beta lipoprotein: relationship to angiographically proven coronary heart disease and to Lp(a) lipoprotein. In: Schettler G, Weizel A, eds. Atherosclerosis III: proceedings of the Third International Symposium. New York: Springer-Verlag, 1974:481-487.

Furberg CD. Possible yields of various forms of interventions after myocardial infarction. In: Hjalmarson A, Wilhelmsen L, eds. Acute and long-term management of myocardial ischemia. Molndal: Lindgren & Soner, 1978:309-311.

Furberg CD, Friedewald WT. The effects of chronic administration of beta-blockade on long-term survival following myocardial infarction. In: Braunwald E, ed. Beta-adrenergic blockade: a new era in cardiovascular medicine. New York: Excerpta Medica, 1978:171-177.

BIBLIOGRAPHY: (Chapters in Books Continued):

- Furberg CD. The role of beta-blockers in cardioprotection. In: Laragh JH, Buhler FR, Seldin DW, eds. *Frontiers in hypertension research*. New York: Springer-Verlag, 1981:495-499.
- Furberg CD. Who should fund clinical trials? In: Morganroth J, Moore EN, eds. *The evaluation of beta blocker and calcium antagonist drugs*. Boston: Nijhoff, 1982:262-264.
- Furberg CD, May GS, Eberlein KA, Passamani ER, Demets DL. Secondary trials after myocardial infarction: a review. In: Hauss WH, Wissler RW, eds. *Second Munster International Arteriosclerosis Symposium: clinical implications of recent research results in arteriosclerosis*. Abhandlung der Rheinisch-Westfälischen Akademie der Wissenschaften, Band 70 1983:39-58.
- Furberg CD, May GS. Secondary prevention of myocardial infarction. In: Turner P, Shand DG, eds. *Recent advances in clinical pharmacology*. New York: Churchill Livingstone, 1983:207-221.
- Furberg CD. Beta-Blocker Heart Attack Trial. In: Robertson JIS, Kaplan NM, Caldwell ADS, Speight TM, eds. *International symposium on beta blockade in the 1980s: focus on atenolol*. Drugs 1983;25(suppl 2):314-317.
- Furberg CD. Additional data from the Beta Blocker Heart Attack Trial (BHAT). In: Shand DG. *New Perspectives on Beta Blockers in Patients with Acute Myocardial Infarction: Proceedings of a Symposium*. MEDED Publishers, Inc., Miami, FL, 1983:19-26.
- Furberg CD, Mattson ME. Bestimmung der Lebensqualität in Klinischen Studien. In: Rohde H, Troidl H, eds. *Das Magenkarzinom: Methodik Klinischer Studien und Therapeutischer Ansätze*. Stuttgart: G. Thieme, 1984:57-61. [Ger]
- Furberg CD, Mattson ME. Kriterien für die Auswahl von Untersuchern, Datenqualität und Datenüberwachung bei Multizentrischen Studien. In: Rohde H, Troidl H, eds. *Das Magenkarzinom: Methodik Klinischer Studien und Therapeutischer Ansätze*. Stuttgart: G. Thieme 1984:9-12. [Ger]
- Levy RI, Furberg CD, Rifkind BM. Primary prevention of coronary artery disease. In: Petersdorf RG, et al., eds. *Harrison's principles of internal medicine*. Update V. New York: McGraw-Hill, 1984:47-65.
- Furberg CD, Schucker B, Chesney MA, et al. Report of the working group: mild hypertension. In: Wenger NK, Mattson ME, Furberg CD, Elinson J., eds. *Assessment of quality of life in clinical trials of cardiovascular therapies*. New York: LeJacq, 1984:285-295.
- Frishman WH, Charlap S, Rotmensch HH, Furberg CD. Beta-adrenergic blockade in patients with myocardial infarction: treatment and prevention. In: Frishman WH, ed. *Clinical pharmacology of the beta-adrenoceptor blocking drugs*. Norwalk: Appleton-Century-Crofts, 1984:299-340.
- Friedewald WT, Furberg CD. Clinical trials of modification of mortality during acute myocardial infarction. In: Califf RM, Wagner GS, eds. *Acute coronary care: principles and practice*. Boston: Nijhoff, 1985:145-155.
- Frommer PL, Furberg C. Beta-blocking drugs in the prevention of sudden cardiac death. In: Morganroth J, Horowitz LN, eds. *Sudden cardiac death*. Orlando: Grune & Stratton, 1985:249-256.
- Frishman WH, Laifer LI, Furberg CD. Beta-adrenergic blockers in the prevention of sudden death. In: Morganroth J, Horowitz LN, eds. *Sudden cardiac death*. Orlando: Grune & Stratton, 1985:249-264.

BIBLIOGRAPHY: (Chapters in Books Continued):

- Frommer PL, Furberg CD. The role of beta-blockers in the prevention of sudden cardiac death in the postinfarction patient. In: El-Sherif N, Reddy CVR, eds. *The pathophysiology and pharmacotherapy of myocardial infarction*. Orlando: Academic Press, 1986:347-369.
- Shephard RJ, Wenger NK, Furberg CD, et al. Education of the aged cardiac patient. In: Wenger NK, ed. *The education of the patient with cardiac disease in the twenty-first century*. New York: LeJacq, 1986:406-409.
- Cutler JA, Furberg CD. Prevention of stroke: evidence from clinical trials. In: Fidge NH, Nestel PG, eds. *Atherosclerosis VII*. Amsterdam: Excerpta Medica, 1986:587-591.
- Furberg CD, Cutler JA, Probstfield JL, Page L, Hulley SB. The systolic hypertension in the elderly program. In: Strasser T, Ganten D, eds. *Mild hypertension: from drug trials to practice*. New York: Raven, 1987:59-63.
- Furberg CD. Trials of beta-blocker therapy in myocardial infarction. In: Roberts R, ed. *Current perspectives in coronary care: selected proceedings of two symposia: Bermuda, August 14-17, 1986, San Diego, August 22-25, 1986*. Princeton: Excerpta Medica, 1987:23-30.
- Yusuf S, Furberg CD. Single factor trials: control through life-style changes. In: Olsson AG, ed. *Atherosclerosis: biology and clinical science*. Edinburgh: Churchill Livingstone, 1987:389-391.
- Furberg CD, Cutler J. Multiple factor intervention: controlled trials. In: Olsson AG, ed. *Atherosclerosis: biology and clinical science*. Edinburgh: Churchill Livingstone, 1987:399-401.
- Furberg C. What CHF trials have shown to date and what is needed? In: Morganroth J, Moore EN, eds. *Congestive heart failure*. Boston: Nijhoff, 1987:251-254.
- Furberg CD, Cutler JA, MacMahon SW, Yusuf S. Clinical trials in hypertension and congestive heart failure. In: Beamish RE, Panagia V, Dhalla NS, eds. *Pharmacological aspects of heart disease: proceedings of an international symposium on heart metabolism in health and disease and the Third Annual Cardiology Symposium of the University of Manitoba, July 8-11, 1986, Winnipeg, Canada*. Boston: Nijhoff, 1987:89-95.
- MacMahon SW, Furberg CD, Cutler JA. Women as participants in trials of the primary and secondary prevention of cardiovascular disease: Part I. Primary prevention: The hypertension trials. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. *Coronary Heart Disease in Women: Proceedings of a Workshop*. New York: Haymarket Doyma Inc., 1987:233-240.
- Furberg CD, Friedman LM, MacMahon SW. Women as participants in trials of the primary and secondary prevention of cardiovascular disease. Part II. Secondary prevention: The Beta-Blocker Heart Attack Trial and the Aspirin Myocardial Infarction Study. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. *Coronary Heart Disease in Women: Proceedings of a Workshop*. New York: Haymarket Doyma Inc., 1987:241-246.
- Furberg CD. The secondary prevention trials: lessons learned, questions raised. In: Gorlin, ed. *Postgraduate Medicine: A quarter-century of beta blockade*. New York: BMI/McGraw-Hill, 1988:83-89.
- Furberg CD, Craver DM. Secondary prevention: Life-style interventions. In: Higgins M, Luepker RV, eds. *Trends in coronary heart disease mortality: the influence of medical care*. NY: Oxford University Press, 1988:227-231.
- Furberg CD, Cutler JA, MacMahon SW. Principles of clinical trials, with an example from neurologic disease. In: Vinken PJ, Bruyn GW, Klawans HL, eds. *Handbook of Clinical Neurology*. Elsevier Science Publishers, 1988:459-467.

BIBLIOGRAPHY: (Chapters in Books Continued):

Furberg CD, Byington RP. Beta adrenergic blockers in patients with acute myocardial infarction. In: Pepine CG, ed. Acute Myocardial Infarction. Cardiovascular Clinics, Philadelphia, PA, 1989;235-248.

Byington RP, Furberg CD. Beta-blockers during and after acute myocardial infarction. In: Francis GS, ed. Modern Coronary Care. Little Brown and Co. Publishers, Boston MA, 1989:511-539.

Furberg CD. Therapy for heart failure: implications for improved survival. In: Sonnenblick, Laragh, Lesch, ed. ACE inhibition: From mechanism to therapy. Excerpta Medica, Princeton, NJ, 1989:218-224.

Furberg CD. Impact of clinical trials on clinical practice. In: Wolff, Fleckenstein, Philipp, eds. Drug Research and Drug Development in the 21st Century. Arzneim-Forsch/Drug Res. 1989;39(II):986-988.

Furberg CD. What do new cardiovascular agents (e.g. antiarrhythmic drugs) have to show to establish a favorable risk versus benefit ratio to obtain approvability? - Clinical viewpoint. In Morganroth J, ed. Ninth Annual Proceedings, Symposium on New Drugs and Devices, Philadelphia, PA, 1989:153-156.

Furberg CD, Byington RP, Espeland M. Should a change in the atherosclerotic process be required for approval of new hypolipidemic agents. In Morganroth J, ed. Ninth Annual Proceedings, Symposium on New Drugs and Devices, Philadelphia, PA, 1989:233-239.

Probstfield JL, Applegate WB, Curb JD, Borhani NO, Hawkins CM, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page LB, Perry HM, Smith WM. The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data. In: Omae T, Zanchetti A, eds. How should elderly hypertensive patients be treated? Springer-Verlag, Tokyo, 1989:135-142.

Wenger NK, Furberg CD. Cardiovascular Disorders. In: Spilker B, ed. Quality of Life Assessments in Clinical Trials. Raven Press, 1990:335-345.

Probstfield JL, Furberg CD. Systolic hypertension in the elderly: Controlled or uncontrolled. In: Frohlich ED, ed. Cardiovascular Clinics. Philadelphia: F. A. Davis Co. 1990:65-84.

Byington RP, Worthy J, Craven T, Furberg CD. Beta-Blockers after a myocardial infarction: Do their effects on blood lipids counteract the favorable effects of beta-blockade? In: Ischinger T, Gohlke H, eds. Strategies in Primary and Secondary Prevention of Coronary Artery Disease. W. Zuckschwerdt Verlag, 1992:113-131.

Cutler JA, Furberg CD. The clinical trials: a selective review. In: Lenfant C, Roccella E, eds. National High Blood Pressure Program -- 20 years of achievement. National Heart, Lung, and Blood Institute, Bethesda. 1992:79-86.

Manolio TA, Furberg CD. Epidemiology of sudden cardiac death. In: Myerburg RJ, Akhtar M, Ruskin J, eds. Sudden Cardiac Death. Wayne, PA: Andover Medicinal Publishers, Inc. 1994:3-20.

Psaty BM, Furberg CD. Treatment trials: morbidity and mortality. In: Black H, Izzo JL, eds. Hypertension Primer. 1993:192-201.

Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control. What has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension, Physiology, Diagnosis, and Management, Second Edition. Raven Press, Ltd., New York, 1995.

BIBLIOGRAPHY: (Chapters in Books Continued):

Furberg CD, Byington RP, Riley W. B-Mode ultrasonography: A noninvasive method for assessing atherosclerosis. In: Willerson JT, Cohn JN, eds. *Cardiovascular Medicine*. Churchill Livingstone, New York, 1995.

Byington RP, Furberg CD. Beta blockers during and after acute myocardial infarction. In: Francis GS and Alpert, JS, eds. *Coronary Care* (2nd Edition). Little Brown and Company, Boston, MA, 1995.

Furberg CD, Manolio TA. Cardiovascular disease in the elderly. In: Yusuf S, Wilhelmsen L, eds. *Advanced Issues in Prevention and Treatment of Atherosclerosis*. Warwick Printing Company Ltd, United Kingdom, 1996, pp.27-35

Furberg CD, Psaty BM, Cutler JA. Blood pressure and cardiovascular disease. In: Yusuf S, ed. *Evidence Based Cardiology*. BMJ Books, London, 1998:226-238.

Psaty BM, Furberg CD. Treatment trials: morbidity and mortality. In: Black H, Izzo JL, eds. *Hypertension Primer*, 2nd Edition, 1998.

Crouse JR, Furberg CD, Byington RP, Riley W. B-mode ultrasound: A noninvasive method for assessing atherosclerosis. In: Willerson JT, Cohn JN, eds. *Cardiovascular Medicine* (2nd Edition). Churchill Livingstone, New York, 2000.

Journal Articles

Furberg C, Ringqvist T. Effekt av penicillin pa fysisk arbetsformaga och upplevelsen av trotthet under arbete. *Sven Laekartidn* 1963;60:2650-2656. [Swe]

Holmlund D, Furberg C. Untersuchungen zur wirkung von papaverin auf den gestauten ureter. *Z Urol* 1964;57:633-637. [Ger]

Furberg C, Koch G, Ostlund H. Die wirkung einer ganglienblockierenden substanz auf die orthostatische reaktion und die korperliche leistungsfahigkeit in liegender und sitzender stellung beim normalen. *Aerztl Forsch* 1966;20:305-307. [Ger]

Furberg C, Tengblad CF. Adrenergic beta-receptor blockade and the effect of hyperventilation on the electrocardiogram. *Scand J Clin & Lab Invest* 1966;18:467-472. Furberg C. Adrenergisk beta-receptor-blockad vid EKG-diagnostik i samband med arbetsprov. *Sven Laekartidn* 1966;63:3349-3354. [Swe]

Furberg C. Adrenergic beta-blockade and electrocardiographical ST-T changes. *Acta Med Scand* 1967;181:21-32.

Furberg C. Adrenergic beta-receptor and the relationship between physical working capacity, heart volume and the total amount of hemoglobin. *Scand J Clin Lab Invest* 1967;19:164-170.

Arvedson O, Furberg C, Linderholm H. The effect of a ganglionic blocking agent (chlorisondamine) on electrocardiogram, physical working capacity and hemodynamics in patients with vasoregulatory asthenia. *Acta Med Scand* 1967;182(suppl 472):36-53.

Bergman F, Furberg C. Adrenergic beta-receptor blockade and ECG changes or organic origin. *Scand J. Clin Lab Invest* 1967;19:274-279.

Furberg C, Jacobsson KA. Propranolol and angina pectoris: an analysis of the different responses to the drug in patients with angina pectoris. *Acta Med Scand* 1967;181:729-736.

BIBLIOGRAPHY: (Journal Articles Continued)

- Furberg C. Adrenergic beta-blockade and physical working capacity. *Acta Med Scand* 1967;182:119-127.
- Astrand I, Furberg C, et al. The "Minnesota code" for ECG classification: adaptation to CR leads and modification of the code for ECGs recorded during and after exercise. *Acta Med Scand* 1967;183(suppl 481):1-25.
- Furberg C. Effects of repeated work tests and adrenergic beta-blockade on electrocardiographic ST and T changes. *Acta Med Scand* 1968;183:153-161.
- Furberg C, Schmalensee G. Beta-adrenergic blockade and central circulation during exercise in sitting position in healthy subjects. *Acta Physiol Scand* 1968;73:435-446.
- Furberg C, Linderholm H. Effects of hyperventilation on ECG in patients with circulatory disturbances. *Acta Med Scand* 1969;185:167-174.
- Furberg C, Morsing C. Adrenergic beta-receptor blockade in neurocirculatory asthenia: a clinical trial of a new beta-receptor blocking agent with special reference to prognosis of therapeutic effect. *Pharmacol Clin* 1969;1:168-171.
- Furberg CD, Michaelson G. Effect of Aptin, a beta-adrenergic blocking agent, in arterial hypertension. *Acta Med Scand* 1969;186:447-450.
- Furberg C. EKG-diagnostik av funktionella ST-och T-sankningar. *Opusc Med* 1969;14:356-358. [Swe]
- Furberg C, Lundkvist L, Svardsudd K. Preventiv kardiologisk verksamhet i Norrbotten. *Sven Laekartidn* 1972;62:143-146. [Swe]
- Dahlen G, Ericson C, Furberg C. Electrophoresis of lipoproteins on cellulose acetate membrane. *Acta Med Scand* 1972;192(suppl 531):5-9.
- Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Angina of effort and an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):11-15.
- Dahlen G, Ericson C, Furberg C, Lundkvist L, Svardsudd K. Familial occurrence of an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):17-21.
- Dahlen G, Ericson C, Furberg C. Variations in pre-beta lipoproteins after a test meal. *Acta Med Scand* 1972;192(suppl 531):21-24.
- Dahlen G, Ericson C, Furberg C. Myocardial infarction and an extra pre-beta lipoprotein fraction. *Acta Med Scand* 1972;192(suppl 531):25-29.
- Adolfsson L, Areskog NH, Furberg C, Granath A, Zetterquist S. Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency. *Eur J Clin Pharmacol* 1972;5:37-43.
- Furberg C, Ringqvist I. Achilles reflex time and sympathetic tone. *Ups J Med Sci* 1973;78:89-92.
- Dahlen G, Ericson C, Furberg C. Pre-beta-1 -ett specifikt lipoprotein? *Sven Laekartidn* 1973;70:2149-2150. [Swe]

BIBLIOGRAPHY: (Journal Articles Continued):

- Adolfsson L, Areskog NH, Furberg C, Johnsson G. Effects of single doses of alprenolol and two cardioselective beta-blockers (H87/07 and H93/26) on exercise-induced angina pectoris. *Eur J Clin Pharmacol* 1974;7:111-118.
- Furberg CD. Beta-adrenergic receptor blocking drugs in hypertrophic cardiomyopathy, autonomically mediated cardiovascular functional disorders and Fallot's tetralogy. *Drugs* 1974;7:106-117.
- Frick MH, Dahlen G, Furberg C, Ericson C, Wiljasalo M. Serum pre-beta-1-lipoprotein fraction in coronary atherosclerosis. *Acta Med Scand* 1974;195:337-340.
- Furberg C, Hornell H. Familial QT prolongation and risk of sudden death. *Acta Paediatr Scand* 1975;64:777-782.
- Zetterquist S, Furberg C, Ringqvist I, Soderholm B. Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris. *Curr Ther Res* 1975;17:139-148.
- Boberg J, Boberg M, Furberg C, Isacsson SQ. "Lipid Research Clinics" - nytt begrepp i klinisk atherosclerosforskning. *Sven Laekartidn* 1975;72:2517-2521. [Swe]
- Furberg C, Isacsson SO. Rokstopp ger forlangt liv! *Sven Laekartidn* 1975;72:2936-2938. [Swe]
- Furberg C, Heinrich G, Hallen J, et al. Lang Q-T syndromet. *Sven Laekartidn* 1975;72:4620-4625. [Swe]
- Furberg CD, Romo M, Linko E, Siltanen P, Tibblin G, Wilhelmsen L. Sudden coronary death in Scandinavia: a report from Scandinavian coronary heart disease registers. *Acta Med Scand* 1977;201:553-557.
- Isacsson SO, Borgstrom B, Lindgren G, Furberg C, Hovstradius S, Lundkvist B. Naringsintag och kostvanor hos 58-åriga man. *Naeringsforskning* 1978;22:11-16. [Swe]
- Aspirin Myocardial Infarction Study Research Group. A randomized controlled clinical trial of aspirin in persons recovered from myocardial infarction. *JAMA* 1980;243:661-669.
- Rautaharju PM, Prineas RJ, Crow RS, Seale D, Furberg C. The effect of modified limb electrode positions on electrocardiographic wave amplitudes. *J Electrocardiol* 1980;13:109-114.
- Furberg CD. Principles of clinical trials: US viewpoint. *Triangle* 1980;19:99-102.
- May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. *Circulation* 1981;64:669-673.
- Beta-Blocker Heart Attack Trial Research Group. Beta-Blocker Heart Attack Trial: design features. *Controlled Clin Trials* 1981;2:275-285.
- Beta-Blocker Heart Attack Trial Research Group. How informed is informed consent? The BHAT experience. *Controlled Clin Trials* 1981;2:287-303.
- Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. *JAMA* 1982;247:1707-1714.
- Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. *JAMA* 1982;248:1465-1477.
- Friedewald WT, Furberg CD. Key references: Clinical trials. *Circulation* 1982;65:213-215.

BIBLIOGRAPHY: (Journal Articles Continued):

- May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. *Prog Cardiovasc Dis* 1982;24:331-352.
- May GS, Furberg CD, Eberlein KA, Geraci BJ. Secondary prevention after myocardial infarction: a review of short-term acute phase trials. *Prog Cardiovasc Dis* 1983;25:335-359.
- Furberg CD, Bell RL. Effect of beta-blocker therapy on recurrent nonfatal myocardial infarction. *Circulation* 1983;67(suppl I):183-185.
- Furberg CD, Byington RP. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. *Circulation* 1983;67(suppl I):198-1101.
- Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: II. Morbidity results. *JAMA* 1983;250:2814-2819.
- Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. *Am J Cardiol* 1983;52:32C-36C.
- The Coronary Drug Project Research Group. Blood pressure in survivors of myocardial infarction. *J Am Coll Cardiol* 1984;4:1135-1147.
- Furberg CD. Clinical value of intracoronary streptokinase. *Am J Cardiol* 1984;53:626-627.
- Frishman WH, Furberg CD, Friedewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. *N Engl J Med* 1984;310:830-837.
- Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. *Circulation* 1984;69:761-765.
- Furberg CD, May GS. Effect of long-term prophylactic treatment on survival after myocardial infarction. *Am J Med* 1984;76(6A):76-83.
- Wenger NK, Mattson ME, Furberg CD, Elinson J. Assessment of quality of life in clinical trials of cardiovascular therapies. *Am J Cardiol* 1984;54:908-913.
- Friedewald WT, Furberg CD, May GS. Aspirin and myocardial infarction. *Cardiovasc Rev & Rep* 1984;5:1285-1289.
- Frishman WH, Furberg CD, Friedewald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. *Curr Probl Cardiol* 1984;9:1-50.
- The Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. *Am J Cardiol* 1985;55:1-15.
- The Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. *Am J Cardiol* 1985;55:16-24.
- Furberg CD, Yusuf S, Thom TJ. Potential for altering the natural history of congestive heart failure: need for large clinical trials. *Am J Cardiol* 1985;55:45A-47A.

BIBLIOGRAPHY: (Journal Articles Continued):

- Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. *Am J Cardiol* 1985;55:1110-1113.
- Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. *Clin Pharmacol Ther* 1985;38:509-518.
- Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. *Eur Heart J* 1985;6:556-585.
- Hulley SB, Furberg CD, Gurland B, et al. Systolic hypertension in the elderly program (SHEP): antihypertensive efficacy of chlorthalidone. *Am J Cardiol* 1985;56:913-920.
- Cutler JA, Furberg CD. Drug treatment trials in hypertension: a review. *Prev Med* 1985;14:499-510.
- Furberg CD (for the BHAT Study Group). The Beta-Blocker Heart Attack Trial. *Z Kardiol* 1985;74(suppl 6):159-165.
- Yusuf S, Wittes J, Bailey R, Furberg C. Digitalis - a new controversy regarding an old drug: the pitfalls of inappropriate methods. *Circulation* 1986;73:14-18.
- Beta-Blocker Heart Attack Trial Research Group. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. *J Am Coll Cardiol* 1986;7:1-8.
- Rautaharju PM, Prineas RJ, Eifler WJ, Furberg CD, Neaton JD, Crow RS, Stamler J, Cutler JA. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. *J Am Coll Cardiol* 1986;8:1-10.
- MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. *Prog Cardiovasc Dis* 1986;24(suppl 1):99-118.
- Rautaharju PM, Broste SK, Prineas RJ, Eifler WJ, Crow RS, Furberg CD. Quality control procedures for the resting electrocardiogram in the Multiple Risk Factor Intervention Trial. *Controlled Clin Trials* 1986;7:46S-65S.
- Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. *Prev Med* 1986;15:254-273.
- Crow RS, Rautaharju PM, Prineas RJ, et al. Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at high risk of symptomatic coronary heart disease. *Am J Cardiol* 1986;57:1075-1082.
- Smith WM, Feigal DW, Furberg CD, et al. Use of diuretics in treatment of hypertension in the elderly. *Drugs* 1986;31(suppl 4):154-164.
- The Working Group on Hypertension in the Elderly. Statement on hypertension in the elderly. *JAMA* 1986;256:70-74.
- Furberg CD, Yusuf S. Effect of drug therapy on survival in chronic heart failure. *Adv Cardiol* 1986;34:124-130.
- Furberg CD. Overview of completed sudden death trials: US experience. *Cardiology*, 1987;74(suppl 2):24-31.

BIBLIOGRAPHY: (Journal Articles Continued):

MacMahon SW, Cutler JA, Neaton JD, Furberg CD, Cohen JD, Kuller LH, Stamler J, for the Multiple Risk Factor Intervention Trial Research Group. Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies. *J Hypertens* 1986;4(suppl 6):S14-S17.

Perry HM Jr, McDonald RH, Hulley SB, Smith WM, Furberg CD, Greenlick MR, Kuller LH, Schnaper HW, Schoenberger JA, Vogt TM. Systolic hypertension in the elderly program, pilot study (SHEP-PS): morbidity and mortality experience. *J Hypertens* 1986;4(suppl 6):S21-S23.

Furberg CD, Morgan TM. Lessons from overviews of cardiovascular trials. *Stat Med* 1987;6:295-303.

Kostis JB, Byington R, Friedman LM, Goldstein S, Furberg C, for the BHAT Study Group. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. *J Am Coll Cardiol* 1987;10:231-242.

Furberg CD. Secondary prevention trials after acute myocardial infarction. *Am J Cardiol* 1987;60:28A-32A.

Dimsdale JE, Ruberman W, Carleton RA, DeQuattro V, Eaker E, Eliot RS, Furberg CD, Irvin CW Jr, Lown B, Shapiro AP, Shumaker SA. Task force 1: sudden cardiac death: stress and cardiac arrhythmias. *Circulation* 1987;76(suppl I):I-198-I-201.

Costa PI Jr, Krantz DS, Blumenthal JA, Furberg CD, Rosenman RH, Shekelle RB. Task force 2: psychological risk factors in coronary artery disease. *Circulation* 1987;76(suppl I):I-145-I-149.

Shapiro AP, Alderman MH, Clarkson TB, Furberg CD, Jesse MJ, Julius S, Miller RE, Pitt B. Task force 4: behavioral consequences of hypertension and antihypertensive therapy. *Circulation* 1987;76(suppl I):I-101-I-103.

Davis BR, Furberg CD, Williams CB. Survival analysis of adverse effects data in the Beta-Blocker Heart Attack Trial. *Clin Pharmacol Ther* 1987;41:611-615.

Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. *Cardiovascular Drugs and Therapy* 1987;1:343-344.

Furberg CD. Secondary prevention trials after myocardial infarction. *J Cardiovasc Pharm* 1988;12(Suppl. I):S83-S87.

Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis -- A review. *Stroke* 1988;19:423-430.

Furberg CD, Black DM. The Systolic Hypertension in the Elderly pilot Program: Methodological issues. *Eur Heart J* 1988;9:223-227.

Wenger NK, Furberg CD, Pitt E. Coronary heart disease in the elderly: Review of current knowledge and research recommendations. *Clin. Cardiol* 1988;11:262-264.

The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. *J Clin Epidemiol* 1988;41:1147-1208.

Furberg CD. Beta blockade during and after acute MI: Which patients will benefit? *Ill Med* 1988;3:2-15.

The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients. *Eur Heart J* 1988;9:8-16.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD, Borhani NA, Byington RP. Multicenter Isradipine Diuretic Atherosclerosis Study: Design features. *Am J Med* 1989;86(4A):37-39.

Prough DS, Furberg CD. Nimodipine and the "No-reflow Phenomenon"-Experimental Triumph, Clinical Failure? *Anesthesia and Analgesia*, 1989;68:431-435.

Furberg CD, Hunt JC. The National Heart, Lung, and Blood Institute Workshop on Antihypertensive Drug Treatment - The Benefits, Costs, and Choices. *Hypertension* 1989;13(suppl I):I-1.

Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. *Hypertension* 1989;13(suppl I):I-36-I-44.

Furberg CD, Cutler JA. Diuretic agents versus beta-blockers - comparison of effects on mortality, stroke, and coronary events. *Hypertension* 1989;13(suppl I):I-1-I-61.

Furberg CD, Cutler JA. Implications for research. *Hypertension* 1989;13(suppl I):I-171-I-172.

Perry HM, Jr., Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, Greenlick MR, Kuller LH, Schnaper HW, Schoenberger JA, Vogt TM, Wolf PA, Hulley SB. Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) Pilot Study. *Stroke* 1989;20:4-13.

Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. *BMJ* 1989;299:1187-1192.

Levy RI, Blankenhorn D, Davis CE, Gordon DJ, Furberg C, Huttunen J, Levine RJ, Passamani E, Yusuf S. Workshop V Intervention Studies. *Circulation* 1989;80:739-743.

Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, Furberg CD, Hawkins CM, Lakatos E, Page LB, Perry HM, Schron E, Smith WM. The Systolic Hypertension in the Elderly Program (SHEP): An intervention trial on isolated systolic hypertension. *Clin. and Exper. Hyper. - Theory and Practice*, 1989;A11:973-989.

Furberg CD. Proposed guidelines for the clinical evaluation of drugs for the treatment of congestive heart failure: a United States viewpoint. *Curr Opin Cardiol* 1989;4(3):547-552.

Byington RP, Worthy J, Craven T, Furberg CD. Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction - The BHAT Experience. *Am J Cardiology*, 1990;65(20):1287-1291.

Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. *BMJ* 1990;300:902-903.

The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. *JAMA* 1990;263:1795-1801.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;265:3255-3264.

Furberg CD. Organizing Multicenter Trials : Lessons from cardiovascular prevention trials. *Prev Med* 1991;20:158-161.

BIBLIOGRAPHY: (Journal Articles Continued):

Fried LP, Borhani NO, Enright P, Furberg CD, et al. The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol* 1991;1:263-276.

Borhani NO, Applegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield JL. Systolic Hypertension in the Elderly Program Part I: Rationale and design. *Hypertension* 1991;17:II-2-II-15.

Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, Kirkpatrick CH, Strauss HC, Smith TW. Digoxin immune fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. *J Am Coll Cardiol* 1991;17:590-598.

Margitic SE, Bond MG, Crouse JR, Furberg CD, Probstfield JL. Progression and regression of carotid atherosclerosis in clinical trials. *Arteriosclerosis* 1991;11:443-451.

Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists following myocardial infarction in light of the DAVIT - II and other recent studies. *Am J Cardiol* 1991;67:1295-1297.

Yusuf S, Furberg CD. Are we biased in our approach to treating elderly patients with heart disease? (Editorial) *Am J Cardiol* 1991;68:954-956.

Furberg CD, Yusuf S. Antiarrhythmics and VPD suppression. (Editorial) *Circulation* 1991;84:928-930.

Manolio TA, Furberg CD. Age as a predictor of outcome: What role does it play? (Editorial) *Am J Med* 1992;92:1-6.

Morgan T, Furberg C. Commentary on "The use of subjective rankings in clinical trials with an application to cardiovascular disease." *Stat Med* 1992;11:443-445.

Furberg CD, Manolio TA, Psaty BM, Bild DE, Borhani NO, Newman A, Tabatznik B, Rautaharju PM for the Cardiovascular Health Study Collaborative Research Group. Major electrocardiographic abnormalities in persons aged 65 years and older (The Cardiovascular Health Study). *Am J Cardiol* 1992;69:1329-1335.

Manolio TA, Furberg CD, Wahl PW, Tracy RP, Borhani NO, Gardin JM, Fried LP, O'Leary DH, Kuller LH for the CHS Collaborative Research Group. Eligibility for cholesterol referral in community-dwelling older adults. The Cardiovascular Health Study. *Ann Intern Med* 1992;116:641-649.

Fletcher AE, Bulpitt CJ, Chase DM, Collins WCJ, Furberg CD, Goggins TK, Hewett AJ, Neiss AM. Quality of life with three antihypertensive treatments: cilazapril, atenolol, nifedipine. *Hypertension* 1992;19:499-507.

Steinberg D, and Workshop Participants. Antioxidants in the prevention of human atherosclerosis . Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop. *Circulation* 1992;85:2338-2345.

ACAPS Cooperative Study Group. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). *Controlled Clin Trials* 1992;13:293-314.

Psaty BM, Furberg CD, Kuller LH, Borhani NO, Rautaharju PM, O'Leary DH, Bild DE, Robbins J, Fried LP, Reid C. Isolated systolic hypertension and subclinical cardiovascular disease in the elderly: initial findings from the Cardiovascular Health Study. *JAMA* 1992;268:1287-1291.

BIBLIOGRAPHY: (Journal Articles Continued):

Crouse JR, Byington RP, Bond MG, Espeland MA, Sprinkle JW, McGovern M, Furberg CD. Pravastatin, lipids, and atherosclerosis in the carotid arteries: Design features of a clinical trial with carotid atherosclerosis outcome. *Controlled Clin Trials* 1992;13:495-506.

Riley WA, Barnes RW, Applegate WB, Dempsey R, Hartwell T, Davis VG, Bond MG, Furberg CD. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis: The Asymptomatic Carotid Artery Plaque Study (ACAPS). *Stroke* 1992;23:1062-1068.

Wofford JL, Hickey AR, Ettinger WH, Furberg CD. Lack of age-related differences in the clinical presentation of digoxin toxicity. *Arch Intern Med* 1992;152:2261-2264.

Probstfield JL, Byington RP, Egan DA, Espeland MA, Margitic SE, Riley WA, Furberg CD. Methodological issues facing studies of atherosclerotic change. *Circulation* 1993;87(supp II):II-74-II-81.

Furberg CD. Commentary on "Can we measure and predict atherosclerotic progression?" *Circulation* 1993;87(supp II):II-82.

Furberg CD, Borhani NO, Byington RP, Gibbons ME, Sowers JR. Calcium antagonists and atherosclerosis: The Multicenter Isradipine Diuretic Atherosclerosis Study. *Am J Hypertens* 1993;6:24S-29S.

Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, Longstreth WT, Jr., Weiss NS, Wagner EH, Prentice R, Furberg CD. A review of the association of estrogens and progestins with cardiovascular disease in post-menopausal women. *Arch Intern Med* 1993;153:1421-1427.

Manolio TA, Furberg CD, Shemanski L, Psaty BM, Bush TL, O'Leary DH, Tracy RP for the CHS Collaborative Research Group. Associations of post-menopausal estrogen use with cardiovascular disease and its risk factors in older women. *Circulation* 1993;88:2163-2171.

Teo KK, Yusuf S, Furberg CD. Effects of prophylactic anti-arrhythmic drug therapy in acute myocardial infarction. An overview of results from the randomized controlled trials. *JAMA* 1993;270:1589-1595.

Zhou SH, Rautaharju PM, Prineas R, Neaton J, Crow R, Calhoun H, Cutler J, Furberg C, Cohen J for the MRFIT Research Group. Improved ECG Models for estimation of LVH progression and regression incidence by redefinition of the criteria for a significant change in LVH status. *J Electrocardiol* 1994;26:108-113.

Furberg CD, Berglund G, Manolio TA, Psaty BM. Overtreatment and undertreatment of hypertension. *J Intern Med* 1994;235:387-397.

Pearce KA, Furberg CD. The primary prevention of hypertension. *Cardiovasc Risk Factors* 1994;4:147-153.

Pearce KA, Furberg CD. Hypertensive cardiovascular disease and the treatment of hypertension in the elderly. *Curr Opin Nephrol Hyper* 1994;3:213-217.

Manolio TA, Furberg CD, Rautaharju PM, Siscovick D, Newman AB, Borhani NO, Gardin JM, Tabatznik B for the CHS Collaborative Research Group. Cardiac arrhythmias on 24-hour ambulatory electrocardiography in older women and men: The Cardiovascular Health Study. *J Amer Coll Cardiol* 1994;15:916-925.

Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The early termination of clinical trials: Causes, consequences, and control with special reference to trials in the field of arrhythmias and sudden death. *Circulation* 1994;89:2892-2907.

BIBLIOGRAPHY: (Journal Articles Continued):

- Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, Psaty B, Robbins J. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. *Am J Epidemiol* 1994;139:1164-1179.
- Berglund GL, Riley WA, Barnes RW, Furberg CD. Minisymposium: Ultrasound in clinical trials of atherosclerosis. Quality control in ultrasound studies on atherosclerosis. *J Intern Med* 1994;236:581-586.
- Furberg CD, Byington RP, Craven TE. Lessons learned from clinical trials with ultrasound endpoints. *J Intern Med* 1994;236:575-580.
- Furberg CD, Adams Jr HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B for the Asymptomatic Carotid Artery Plaque Study (ACAPS) Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. *Circulation* 1994;90:1679-1687.
- Espeland MA, Hoen H, Byington RP, Howard G, Riley WA, Furberg CD. Spatial distribution of carotid intimal-medial thickness as measured by B-mode ultrasonography. *Stroke* 1994;25:1812-1819.
- Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects: The Cardiovascular Health Study. *Am J Cardiol* 1994;74:236-241.
- Pearson TA, Rapaport E, Criqui M, Furberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization. *Circulation* 1994;90:3125-3133.
- Furberg CD. Lipid-lowering trials: results and limitations. *Am Heart J* 1994;128:1304-8.
- Furberg CD. Challenges to funding of prevention research. *Prev Med* 1994;23:599-601.
- Rautaharju PM, Manolio TA, Psaty BM, Borhani NO, Furberg CD for the CHS Collaborative Research Group. Correlates of QT prolongation in older adults: The Cardiovascular Health Study. *Am J Cardiol* 1994;73:999-1002.
- Armstrong PW, Furberg CD. Clinical Trial Data and Safety Monitoring Boards: The search for a constitution. *Circulation* 1995;91:901-904.
- Wagenknecht LE, Furberg CD, Hammon JW, Legault, BT Troost. Surgical bleeding: unexpected effect of a calcium antagonist. *BMJ* 1995;310:776-7.
- Psaty BM, Koepsell TD, Yanez D, Smith NL, Manolio TA, Heckbert SR, Borhani NO, Gardin JM, Gottdiener J, Rutan GH, Siscovick DS, Furberg CD. Temporal patterns of antihypertensive medication use among older adults, 1989-1992: An effect of the major clinical trials on clinical practice? *JAMA* 1995;273:1436-1438.
- Adams HP, Byington RP, Hoen H, Dempsey R, Furberg CD for the Asymptomatic Carotid Artery Plaque Study (ACAPS) Research Group. Effect of cholesterol-lowering medications on progression of mild atherosclerotic lesions of the carotid arteries and on the risk of stroke. *Cerebrovasc Dis* 1995;5:171-177.
- Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: A new look at old data. *Circulation* 1995;91:2274-2282.
- Margitic SE, Morgan T, Sager MA, Furberg CD. Lessons learned from a prospective meta-analysis. *J Am Geriatr Soc* 1995;43:435-439.

BIBLIOGRAPHY: (Journal Articles Continued):

- Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. *Circulation* 1995;92:1326-1331.
- Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. *Arch Intern Med* 1995;155:829-837.
- Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB. Reduction in cardiovascular events during pravastatin therapy: Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. *Circulation* 1995;92:2419-2425.
- Rautaharju PM, Manolio TA, Furberg CD, Siscovick D, Newman AB, Borhani NO, Gardin JM for the CHS Collaborative Research Group. Ischemic episodes in 24-hour ambulatory electrocardiograms of elderly persons: The Cardiovascular Health Study. *Int J Cardiol* 1995;51:165-175.
- Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II): A clinical trial with atherosclerosis outcome. *Am J Cardiol* 1995;75:455-459.
- Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? *J Am Geriatr Soc* 1995;43:1309-1310 (Editorial).
- Furberg CD, Psaty BM. Should calcium antagonists be first line drugs in hypertension? *Herz* 1995;20:365-369.
- Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? *Arch Intern Med* 1995;155:2157-2161.
- Pearce KA, Furberg CD, Rushing J. Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials. *Arch Fam Med* 1995;4:943-950.
- Furberg CD, Pitt B, Byington RP, Park J-S, McGovern ME for the PLAC I and II investigators. Reduction in coronary events during treatment with pravastatin. *Am J Cardiol* 1995;76:60C-63C.
- Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies: *JAMA* 1995;274:620-625.
- Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD for the ACAPS Research Group. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study (ACAPS) *Am J Cardiol* 1995;76:47C-53C.
- PPP Project Investigators. Design, rationale and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project. A combined analysis of three large-scale randomized trials : Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol & Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). *Am J Cardiol* 1995;76:899-905.
- Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D for the ACAPS Investigators. Estrogen replacement therapy of progression of intimal-medial thickness in the carotid arteries of postmenopausal women. *Am J Epidemiol* 1995;142:1011-1019.

BIBLIOGRAPHY: (Journal Articles Continued):

- Byington RP, Furberg CD, Crouse JR, Espeland MA, Bond MG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). *Am J Cardiol* 1995;76:54C-59C.
- Ashraf T, Hay J, Pitt B, Wittels E, Crouse J, Davidson M, Furberg C, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. *Am J Cardiol* 1996;76:A3-A7.
- O'Leary DH, Polak JF, Kronmal RA, Savage PJ, Borhani NO, Kittner SJ, Tracy R, Gardin JM, Price TR, Furberg CD for the CHS Collaborative Research Group. Thickening of the carotid wall: A marker for atherosclerosis in the elderly? *Stroke* 1996;27:224-231.
- Furberg CD, Psaty BM. Calcium antagonists: Not appropriate as first-line antihypertensive agents. *Am J Hypertens* 1996;9:122-125.
- Espeland MA, Craven TE, Riley WA, Corson J, Davis VG, Romont A, Furberg CD, for the ACAPS Research Group. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. *Stroke* 1996;27:480-485.
- Psaty BM, Siscovick DS, Weiss NS, Koepsell TD, Rosendaal FR, Lin D, Heckbert SR, Wagner EH, Furberg CD. Hypertension and outcomes research: from clinical trials to clinical epidemiology. *Am J Hypertens* 1996;9:178-183.
- Furberg CD, Psaty BM. Correction to the nifedipine meta-analysis. *Circulation* 1996;93:1475-1476.
- Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal hemorrhage with calcium antagonists in hypertensive persons over 67 years old. *Lancet* 1996;347:1061-1065.
- Furberg CD, Hennekens CG, Hulley SB, Manolio T, Psaty BM, Whelton PK. Clinical epidemiology: the conceptual basis for interpreting risk factors. *J Am Coll Cardiol* 1996;27:976-978.
- Rautaharju PM, Manolio TA, Siscovick D, Zhou SH, Gardin JM, Furberg CD, Borhani NO, Newman A, for the CHS Collaborative Research Group. Classification accuracy of electrocardiographic criteria for left ventricular hypertrophy in normalweight and overweight older adults: The Cardiovascular Health Study. *Ann Noninv Electrocardiol* 1996;1:121-132.
- Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright, Jr JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial. (ALLHAT) *Am J Hypertens* 1996;9:342-360.
- Rosendaal FR, Psaty BM, Furberg CD. Calciumantagonisten: veilig of onveilig? *Ned Tijdschr Geneesk* 1996;140:916-918 (Dutch).
- Riley WA, Craven T, Romont A, Furberg CD for the ACAPS Research Group. Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). *Ultrasound Med Biology* 1996;22:405-411.
- Rautaharju PM, Manolio RA, Siscovick D, Zhou SH, Gardin JM, Kronmal R, Furberg CD, Borhani NO, Newman A, for the Cardiovascular Health Study Collaborative Research Group. Utility of new electrocardiographic models for left ventricular mass in older adults. *Hypertens* 1996;28:8-15.
- Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. *Eur Heart J* 1996;17:1142-1147.

BIBLIOGRAPHY: (Journal Articles Continued):

Furberg CD. Aspirin should be used in the primary prevention of coronary heart disease. Pro/Con discussion. *J Coronary Artery Dis Index Reviews*. 1996;11:3,10.

Furberg CD, Psaty BM. Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. *Cardiovasc Drugs Ther* 1996;10:463-466.

Pahor M, Psaty BM, Furberg CD. Calcium channel blockers: What is their role in the treatment of hypertension in renal patients? *J Nephrology* 1996;9:286-290.

Legault C, Furberg CD, Wagenknecht LE, Rogers AT, Stump DA, Coker L, Troost BT, Hammon JW. Nimodipine neuroprotection in cardiac valve replacement. Report of an early terminated trial. *Stroke* 1996;27:593-598.

Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. A review of the health outcomes associated with various anti-hypertensive therapies used as first-line agents. *JAMA* 1997;277:739-745.

Sobel BE, Furberg CD. Surrogates, semantics, and sensible public policy. *Circulation* 1997;95:1661-1663.

Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. *Arch Intern Med* 1997;157:1305-1310.

Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997;96:2455-2461.

Manolio TA, Weinmann GG, Buist AS, Furberg CD, Pinsky JL, Hurd SH. Pulmonary function testing in population-based studies. *Am J Respir Crit Care Med* 1997;15

Byington RP, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, Hunninghake DB, Mancini GB, for the PREVENT Investigators. Rationale, design and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). *Am J Cardiol* 1997;80:1087-1090.

Furberg CD, Psaty BM. JNC VI: timing is everything. *Lancet* 1997;350:1413-1414.

Byington RP, Craven TE, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. *Lancet* 1997;350:1075.

Heckbert SR, Longstreth, Jr WT, Psaty BM, Murros KE, Smith NL, Newman AB, Williamson JD, Bernick C, Furberg CD. The association of antihypertensive agents with MRI white matter findings and with modified mini-mental state examination in older adults. *J Am Geriatr Soc* 1997;45:1423-1433.

Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. *Cancer* 1997;80:1438-47.

Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Controlled Clin Trials* 1998;19:61-109.

Furberg CD. Drug safety: the different perspectives. *Evidence-based Cardiovascular Medicine* 1998;2:1-2. (Editorial)

BIBLIOGRAPHY: (Journal Articles Continued):

- World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. *J Hypertens* 16:127-137.
- Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: Impact of statin trials. *Circulation* 1998;97:946-952.
- Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. *Lancet* 1998;351:689-690.
- Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. *JAMA* 1998;279:1571-1573.
- Psaty BM, Furberg CD. Clinical implications of the WHO/ISH statement on calcium antagonists. *J Hypertens* 1997;15:1197-1200.
- Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. *Am J Hypertens* 1998;11:618-629.
- Crouse JR, Byington RP, Furberg CD. HMG Co-A reductase inhibitor therapy and stroke reduction: An analysis of clinical trials data. *Atherosclerosis* 1998;138:11-24.
- Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart & Estrogen/Progestin Replacement Study (HERS): Design, methods and baseline characteristics. *Controlled Clin Trials* 1998;19:314-335.
- Pahor M, Psaty BM, Furberg CD. New evidence on the prevention of cardiovascular events in hypertensive patients with Type 2 diabetes. *J Cardiovasc Pharmacol* 1998;32:S18-S23.
- Lemaitre RN, Psaty BM, Furberg CD, Gordon DJ, Gottdiener JS, Hulley SB, McDonald RH. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study. *Arch Intern Med* 1998;158:1761-1768.
- Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998;280:605-613.
- Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. *Drugs & Aging* 1998;13:99-108.
- Byington RP, Furberg CD, Craven TE, Pahor M, Sowers JR. Isradipine in pre-diabetic hypertensives. *Diabetes Care* 1998;21:2103-2110.
- Furberg CD. Natural statins and stroke risk. *Circulation* 1999;99:185-188.
- White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kittner SJ, Bovill T, Knepper L. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. *Am J Med* 1999;106:165-171.
- Smith NL, Psaty BM, Furberg CD, White R, Lima JAC, Newman A, Manolio TA. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation [abstract]. *Circulation* 1999;99:1104.
- Pahor M, Furberg CD. Calcium antagonists and cancer. Causation or association? *Cardiovasc Drugs Ther*. 1998;12:511-513.

BIBLIOGRAPHY: (Journal Articles Continued):

- Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD. Assessment and control for confounding by indication in observational studies. *J Am Geriatr Soc* 1999;47:749-754.
- Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener JS. Traditional risk factors and subclinical-disease measures as predictors of first myocardial infarction in older adults. The Cardiovascular Health Study. *Arch Intern Med* 1999;159:1339-1347.
- Byington RP, Evans GW, Espeland MA, Applegate WB, Hunninghake DB, Probstfield J, Furberg CD. Effects of lovastatin and warfarin on early carotid atherosclerosis. Sex-specific analyses. *Circulation* 1999;100:e14-e17.
- Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate endpoints, health outcomes and the drug approval process for treatment of risk factors for cardiovascular disease. *JAMA* 1999;282:786
- Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Prevalence and incidence of cardiovascular disease in adults, 65 years and older, with glucose metabolic disorders, classified by the fasting American Diabetes Association (ADA) criteria and the World Health Organization (WHO) criteria: A report from the Cardiovascular Health Study. *Lancet* 1999;354:622-625.
- Herrington DM, Furberg CD. Hormone therapy: Time for replacement? *Eur Heart J* 1999;20:1285-1286.
- Furberg CD, Herrington D, Psaty BM. Class Effects. Are drugs within a class interchangeable? *Lancet* 1999;354:1202-1204.
- Furberg CD. Hypertension and diabetes: Current issues. *Am Heart J* 1999;138:S400-S405.
- Weber MA, Furberg CD. Comparisons in a competitive world. When is one drug superior to another? *Am J Hypertens* 2000;13:457-459.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone . The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2000;283:1967-1975.
- Grady D, Wenger N, Herrington D, Khan S, Hulley S, Furberg C, Hunninghake D, Vittinghoff E, for the Heart Estrogen/progestin Replacement Study (HERS) Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/Progestin Replacement Study (HERS). *Ann Intern Med* 2000;132:689-696.
- Furberg CD. Class effects and evidence-based medicine. *Clin Cardiol* 2000;23:IV-15-IV-19.
- Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. *Diabetes Care* 2000;23:888-892.
- Luoto R, Manolio T, Meilahn E, Bhadelia R, Furberg C, Cooper L, Kraut M. Estrogen replacement therapy and MRI-demonstrated cerebral infarcts, white matter changes and brain atrophy in elderly women: The Cardiovascular Health Study. *J Amer Geriatr Soc* 2000;48:467-472.
- Psaty BM, Furberg CD, Pahor M, Alderman M, Kuller L. National guidelines, clinical trials and quality of evidence. *Arch Intern Med* 2000;160:2577-2580.

BIBLIOGRAPHY: (Journal Articles Continued):

- Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller M, Riley W for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000;102:1503-1510.
- Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins M, Keech A, Packard C, Simes J, Byington R, Furberg CD for the Prospective Pravastatin Pooling Project Investigators Group. *Circulation* 2000;102:1893-1900.
- Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on progression of coronary artery atherosclerosis. *N Engl J Med* 2000;343:522-529.
- Knappertz VA, Tegeler CH, Furberg CD, Wesley DJ, Stewart KP, Kitzman DW. Carotid doppler high intensity transient signals in dilated cardiomyopathy. *Am Heart J* 2000;140:e4.
- Psaty BM, Rhoads C, Furberg CD. Evidence-based medicine, the worship of form, and the treatment of high blood pressure. *J Gen Intern Med* 2000;15:755-756.
- Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. *Lancet* 2000;356:1949-1954.
- Crouse, III, JR, Furberg CD. Treatment of dyslipidemia: room for improvement? *Arterioscler Thromb Vasc Biol* 2000;20:2333-2335.
- Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, Furberg CD. Depressive symptoms and risks of coronary heart disease and mortality in the elderly: The Cardiovascular Health Study. *Circulation* 2000;102:1773-1779.
- Klungel OH, Heckbert SR, Longstreth, Jr. WT, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HGM, de Boer A, Psaty BM. Antihypertensive drug therapies and the risk of ischemic stroke. *Arch Intern Med* 2001;161:37-43.
- Pocock S, Furberg CD. Procedures of data and safety monitoring committees. *Am Heart J* 2001;141:289-294.
- Pressel SL, Davis BR, Wright Jr, J, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Payne G, Einhorn PT, Nwachukwu C, Furberg CD. Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Trial to Prevent Heart Attack Trial Controlled Clin Trials (ALLHAT). *Control Clin Trials* 2001;22:29-41.
- Wittes J, Palensky J, Asner D, Julian D, Boissel J-P, Furberg CD, Kulbertus H, Pocock S, Roniker B. Experience collecting interim data on mortality: An example from the RALES Study. *Curr Control Trials Cardiovasc Med* 2001;2:59-62.
- Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard V, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation* 2001;103:163-182.
- Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O'Leary DH, Bryan RN, Anderson M, Lumley T. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: The Cardiovascular Health Study. *Arch Intern Med* 2001;161:1183-1192.

BIBLIOGRAPHY: (Journal Articles Continued):

- Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? *J Am Coll Cardiol* 2001;37:1456-60.
- Furberg CD. The usefulness of information on HDL-cholesterol. Potential pitfalls of conventional assumptions. *Curr Control Trials Cardiovasc Med* 2001;
- Kaplan RC, Heckbert SR, Koepsell TD, Furberg CD, Polak JF, Schoen RE, Psaty BM for the Cardiovascular Health Study Investigators. Risk factors for hospitalized gastrointestinal bleeding among older persons. *J Amer Geriatr Soc* 2001;49:126-133.
- In Press or In Review**
- Heckbert SR, Kaplan RC, Weiss NS, Psaty BM, Lin D, Starr JR, Furberg CD, Anderson GD, LaCroix AZ. Risk of recurrent coronary events in relation to use and recent starting of postmenopausal hormone therapy. *Arch Intern Med.* (In press).
- Furberg CD, Psaty BM, Pahor M, Alderman MH. Clinical implications of recent findings from ALLHAT and other studies of hypertension. *Ann Intern Med* (In press).
- Miller M, Byington R, Hunninghake D, Pitt B, Furberg CD for the PREVENT Investigators. Gender bias and underutilization of lipid lowering therapy in CAD patients at academic U.S. and Canadian Medical Centers. *Arch Intern Med.*
- Marshall RJ, Gottdiener JS, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Manolio TA. Outcomes of congestive heart failure in the elderly. Influence of left ventricular systolic function. The Cardiovascular Health Study. *Arch Intern Med* (Submitted).
- Fitzpatrick A, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives and incident prostate cancer. *Ann Epidemiol* (In press).
- Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, MacMahon SW, Shepherd J for the PPP Investigators. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The Prospective Pravastatin Pooling project (In press).
- Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Furberg CD, Cooper L, Psaty BM, for the Cardiovascular Health Study Investigators. Calcium channel blocker use and gastrointestinal bleeding among older adults. (Submitted).
- Longstreth WT Jr., Bernick C, Fitzpatrick A, Cushman M, Knepper L, Lima J, Furberg CD for the Cardiovascular Health Study Collaborative Research Group. Frequency and predictors of stroke death in 5888 participants in the cardiovascular health study. *Neurology* (In press).
- Kaplan RC, Heckbert SR, Furberg CD, Psaty BM. Predictors of subsequent cardiovascular events among survivors of first hospitalized myocardial infarction. (Submitted)
- Sinzinger H, Fitscha P, Kritz H, Furberg CD. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.
- Rautaharju PM, Nelson JC, Kronmal RA, Zhang Z-M, Robbins J, Gottdiener J, Furberg C, Manolio T, Fried L, Feldman A. T axis deviation is a strong independent risk indicator for cardiac events and all-cause mortality in older men and women ostensibly free from coronary heart disease. The Cardiovascular Health Study (CHS) (Submitted).

BIBLIOGRAPHY: (In Press or In Review Continued)

Mancini GBJ, Miller M, Evans GW, Byington R, Furberg CD, Pitt B, for the PREVENT Study Group. Post-hoc analyses of clinical events and coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT): Implications for Planning and Interpretation of Angiographic Trials. *J Am Coll Cardiol* (Submitted).

Furberg CD, Cutler JA, Davis BR for the ALLHAT Collaborative Research Group. Status of alpha-blocker therapy in the treatment of hypertension: Findings of ALLHAT. *Harrison's Online* (Submitted).

Ferrucci L, Furberg CD, Penninx B WJH, Di Bari M, Williamson JD, Guralnik JM, Applegate WB, Pahor M. Treatment of systolic hypertension in older patients. Who should be treated more aggressively?

Furberg CD, Evans GW. B-mode ultrasonography -- A valuable research tool. (Submitted).

**APPEARS THIS WAY
ON ORIGINAL**